Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001811764-22-000050
Filing Date
2022-05-13
Accepted
2022-05-13 08:17:35
Documents
67
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q pnt-20220331.htm   iXBRL 10-Q 785381
2 EX-31.1 exhibit311-10qx03312022.htm EX-31.1 11439
3 EX-31.2 exhibit312-10qx03312022.htm EX-31.2 12182
4 EX-32 exhibit32-10qx03312022.htm EX-32 8935
  Complete submission text file 0001811764-22-000050.txt   4293546

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pnt-20220331.xsd EX-101.SCH 39380
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT pnt-20220331_cal.xml EX-101.CAL 42225
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT pnt-20220331_def.xml EX-101.DEF 179542
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pnt-20220331_lab.xml EX-101.LAB 447856
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pnt-20220331_pre.xml EX-101.PRE 297229
61 EXTRACTED XBRL INSTANCE DOCUMENT pnt-20220331_htm.xml XML 510543
Mailing Address 4850 WEST 78TH STREET INDIANAPOLIS IN 46268
Business Address 4850 WEST 78TH STREET INDIANAPOLIS IN 46268 (317) 543-9957
POINT Biopharma Global Inc. (Filer) CIK: 0001811764 (see all company filings)

EIN.: 850800493 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39373 | Film No.: 22920334
SIC: 2834 Pharmaceutical Preparations